Target intelligence / Profile preview

Rhodopsin (RHO) P23H mutant allele DNA recognition sequence (RHO P23H DNA)

Target
RHO P23H DNA
Molecular classification
DNA sequence, Gene, G protein-coupled receptor
01

Overview

The P23H mutant rhodopsin allele 22-bp DNA recognition sequence is a specific genomic locus within the Rhodopsin (RHO) gene that contains the c.68C>A point mutation (Source: NIH, GeneReviews). This mutation leads to the production of a misfolded rhodopsin protein, which triggers endoplasmic reticulum stress and apoptosis in rod photoreceptor cells, ultimately causing autosomal dominant retinitis pigmentosa (adRP) (Source: PubMed, PMID: 25101605). As the most prevalent mutation associated with adRP in North America, this DNA sequence represents a critical target for precision medicine. In the context of therapeutic development, this 22-bp sequence serves as the binding site for allele-specific gene-editing tools like CRISPR/Cas9 (Source: Nature Communications, 2014). Experimental therapies, such as EDIT-102, utilize guide RNAs (gRNAs) designed to recognize this specific sequence to induce double-strand breaks only in the mutant allele (Source: Editas Medicine). This targeted disruption aims to silence the toxic mutant gene through non-homologous end joining (NHEJ) while preserving the expression of the healthy wild-type allele. This strategy is designed to halt the progression of retinal degeneration and preserve vision in affected patients (Source: Investigative Ophthalmology & Visual Science, 2018).

Other names
P23H RHO mutation siteRhodopsin P23H alleleRHO c.68C>A sequenceP23H gRNA target site
02

Mechanism of action

Allele-specific gene knockout via CRISPR/Cas9-mediated non-homologous end joining (NHEJ) (Source: Nature, 2017)

03

Biological functions

Genetic template for Rhodopsin protein synthesis (Source: UniProt, P08100)Signal transduction in vision (Source: NIH, StatPearls)
04

Disease associations

Retinitis pigmentosa (Source: NIH, GARD)
05

Safety considerations

Off-target genomic cleavage (Source: Molecular Therapy, 2020)Unintended disruption of the wild-type RHO allele (Source: Nature Communications, 2014)Immune response to Cas9 protein or AAV vector (Source: Science Translational Medicine, 2019)
06

Interacting drugs

EDIT-102 (Source: Editas Medicine)
07

Biomarkers

RHO c.68C>A genotype (Source: NIH, GeneReviews)Outer nuclear layer (ONL) thickness (Source: Ophthalmology, 2019)Rod-mediated electroretinogram (ERG) amplitude (Source: PubMed, PMID: 30125012)

Beyond the preview

Go deeper on Rhodopsin (RHO) P23H mutant allele DNA recognition sequence (RHO P23H DNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rhodopsin (RHO) P23H mutant allele DNA recognition sequence (RHO P23H DNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call